Biome Australia (ASX:BIO) said it received positive results of the core functional characterization studies conducted by the cell culture lab of one of its research partners, according to a Thursday Australian bourse filing.
The in vitro studies investigated the functional characteristics of Biome's Lactobacillus plantarum probiotic strain BMB18 using two types of cell cultures.
Caco-2 epithelial cell culture studies model the intestinal epithelial barrier and were used to study the ability of the strain to repair and prevent intestinal tissue damage.
Transepithelial peripheral blood mononuclear cell culture study was used to stimulate immune responses.
The strain exhibited an ability to "effectively modulate immune responses and inflammation, reduce oxidative stress, and maintain intestinal barrier integrity," per the filing.
The firm's shares fell a little over 3% on market close.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。